ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2013
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01169038 (Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis.BMC pulmonary medicine · 2016Pooled it
- Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis.Chest · 2021Trial
- Immunopathogenesis of Sarcoidosis.Seminars in respiratory and critical care medicine · 2025Review
- Long-Term Macrolides in Chronic Respiratory Diseases: Dusk or a New Dawn? A Narrative Review.Antibiotics (Basel, Switzerland) · 2025Review
- Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.Journal of clinical medicine · 2025Review
- Functional Measures in Non-COPD Chronic Respiratory Diseases: A Systematic Review.Journal of clinical medicine · 2024Review
- The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.American journal of clinical dermatology · 2022Review
- Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.Advanced drug delivery reviews · 2022Review
- Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches.Frontiers in medicine · 2022Review
- A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.Pulmonary therapy · 2021Review
- Stable Extent of Recurrently Active Cardiac and Cutaneous Sarcoidosis.Frontiers in medicine · 2021Article
- Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial.ERJ open research · 2020Article
- Environmental Risk Factors for Sarcoidosis.Frontiers in immunology · 2020Review
- Treatment of Sarcoidosis: A Multidisciplinary Approach.Frontiers in immunology · 2020Review
- Single Cell Transcriptomics Implicate Novel Monocyte and T Cell Immune Dysregulation in Sarcoidosis.Frontiers in immunology · 2020Article
- Refractory Sarcoidosis: A Review.Therapeutics and clinical risk management · 2020Review
- Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.Journal of biomedical science · 2019Review
- Potential immunotherapies for sarcoidosis.Expert opinion on biological therapy · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSarcoidosis is an idiopathic, granulomatous disease for which molecular and immunologic studies have shown an association between it and mycobacterial antigens. Microbial antigens can reduce expression of the tyrosine kinase Lck, which has been associated with sarcoidosis severity. Here we investigate the efficacy of Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin (the CLEAR regimen) for treatment of chronic, pulmonary sarcoidosis.
methodsFifteen chronic, pulmonary sarcoidosis patients with forced vital capacities (FVC) between 45-80% of predicted were enrolled in this open-label trial. The primary efficacy endpoint was change in absolute FVC from baseline to completion of therapy. Secondary endpoints were change in functional capacity measured by Six Minute Walk Distance (6MWD) and quality of life assessment measured by St. George's Respiratory Questionnaire (SGRQ).
resultsOf 15 patients enrolled, 11 completed 4 weeks of therapy, and 8 completed 8 weeks of therapy. The CLEAR regimen was associated with an increase in FVC of 0.23 liters at 4 weeks and 0.42 liters at 8 weeks (P=0.0098 and 0.016, respectively). The 6MWD increased by 87 meters from baseline to 8 weeks (p=0.0078). The mean score of the validated SGRQ was improved at 8 weeks over baseline (p=0.023). Normalized expression of Lck and NF-κB was observed in those with clinical improvement.
conclusionsThe CLEAR regimen is associated with improved absolute FVC, as well as increased functional capacity and quality-of-life in selected chronic pulmonary sarcoidosis patients. Larger, randomized, controlled trials are needed to confirm these findings and to identify patients most likely to benefit from therapy. ClinicalTrials.gov number NCT01169038.
Indexed as
Identifiers
24284293PMC3929334W2105370232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.